ENGN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
enGene Holdings Inc (ENGN) is not a strong buy at the moment for a beginner investor with a long-term strategy. The stock lacks significant positive catalysts, has weak technical indicators, and its financial performance does not show promising growth trends. Analysts have lowered price targets, and there are no recent signals from proprietary trading tools to suggest immediate action. Holding off on investment until clearer positive trends emerge is recommended.
The stock's MACD is negative and contracting, RSI is neutral at 31.319, and moving averages are converging, indicating no clear trend. The stock is trading near its support level (S1: 6.797), but there is no strong bullish signal. Short-term stock trend analysis suggests a 70% chance of a minor decline (-1.49% in the next week, -7.87% in the next month).
Analysts note that the company's detalimogene product has a competitive edge in its market segment.
Recent analyst price target cuts from multiple firms (UBS, Oppenheimer, and Guggenheim) due to increased spending and delayed timelines for product launches. Financial performance shows no revenue growth, negative net income, and declining EPS. No recent news or trading activity from hedge funds, insiders, or Congress to indicate strong interest in the stock.
In Q1 2026, the company reported no revenue growth (0% YoY), a net loss of -$29.75M (improved 20.86% YoY), and a decline in EPS to -0.44 (-8.33% YoY). Gross margin remains at 0%. Financials do not indicate strong growth or profitability.
Analysts are mixed but leaning neutral. UBS maintains a Neutral rating with a reduced price target of $9. Oppenheimer and Guggenheim lowered price targets but maintain Outperform and Buy ratings, respectively, citing potential long-term benefits from the LEGEND trial and detalimogene product. Jefferies initiated coverage with a Buy rating and a $28 price target, highlighting the company's competitive positioning.
